Abstract: Hepatocellular carcinoma (HCC) is a major health problem. It is currently thethird cause of cancer-related death, it is highly prevalent in the Asia–Pacific region and Africa,and is increasing in Western countries. The natural history of HCC is very heterogeneous andprediction of survival in individual patients is not satisfactory because of the wide spectrum ofthe disease. During the past decade, major advances have been achieved in prevention, throughbetter surveillance of patients at risk, and in therapy through better surgical and ablative therapiesand multimodal treatment approaches. Moreover, the increasing knowledge of molecularhepatocarcinogenesis provides the opportunity for targeted therapies. In this setting, the impact ofsorafenib on advanced-stage HCC is a landmark finding in the treatment of liver cancer. The roleof sorafenib administration as adjuvant therapy after curative treatment is being evaluated inclinical studies. Future research should lead to a molecular classification of the disease and amore personalized treatment approach.
|Numero di pagine||11|
|Stato di pubblicazione||Published - 2010|